Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Exclusion Criteria

• •1. Enrollment in another clinical trial
• •2. Hypersensitivity to an agent used for the skin decolonization protocol
• •3. Use within 4 weeks of systemic treatment with immunosuppressive/immunomodulating drugs (corticosteroids, cyclosporine, mycophenolate, JAK inhibitors, azathioprine, methotrexate)
• •4. Phototherapy for AD within 4 weeks
• •5. Treatment with biologics (dupilumab, omalizumab, benralizumab, etc) within sixteen weeks
• •6. Use of topical steroids, topical calcineurin inhibitors or crisaborale within 7 days
• •7. Bleach baths within 7 days of the first Visit
• •8. Use of oral or topical antibiotics within 21 days of the beginning of the study
• •9. Asthmatics receiving more than 500 μg per day of inhaled corticosteroids
• •10. History of (HIV, hepatitis B, hepatitis C, tuberculosis malignancy
• •11. Skin comorbidities that may interfere with assessments: psoriasis, cutaneous T Cell lymphoma,,
• •12. Severe ongoing medical illnesses e.g. cardiovascular, renal disease, autoimmune disease.
• •13. Febrile illness at time of visits
• •14. Suspected immune deficiency or family history of primary immunodeficiency